Renal & Urology News

Atrasentan Reduces Proteinuria in IgA Nephropathy

Atrasentan, an investigational potent and selective oral ETA receptor antagonist, reduced proteinuria at 36 weeks in patients with IgA nephropathy at high risk for progression. Atrasentan treatment ...
The American Journal of Managed Care

FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy

Atrasentan is approved for proteinuria reduction in primary IgA nephropathy, a condition risking kidney failure. The phase 3 ALIGN study showed atrasentan reduced proteinuria by 36.1% compared to ...
FierceBiotech

BioCity's ETA antagonist reduces proteinuria in phase 2 trial of diabetic kidney disease

BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of patients with diabetic kidney disease (DKD), hitting a primary endpoint of a phase ...
Morningstar

BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)

SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ET A) antagonist, SC0062, met the 12-week primary endpoint of a reduction ...
The Victoria Advocate

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...

"Vanrafia is a selective ETA receptor antagonist that effectively reduces proteinuria, a major risk factor in IgAN. Taking early, decisive action is critical to help improve outcomes for these ...